Drugs /

resiquimod

Back to Drugs List

Overview

NCI Definition [1]:
An imidazoquinolinamine and Toll-like receptor (TLR) agonist with potential immune response modifying activity. Resiquimod exerts its effect through the TLR signaling pathway by binding to and activating TLR7 and 8 mainly on dendritic cells, macrophages, and B-lymphocytes. This induces the nuclear translocation of the transcription activator NF-kB as well as activation of other transcription factors. This may lead to an increase in mRNA levels and subsequent production of cytokines, especially interferon-alpha (INF-a) and other cytokines, thereby enhancing T-helper 1 (Th1) immune responses. In addition, topical application of resiquimod appears to activate Langerhans' cells, leading to an enhanced activation of T-lymphocytes. Due to its immunostimulatory activity, this agent may potentially be useful as a vaccine adjuvant.

Clinical Trials

View Clinical Trials for resiquimod

Resiquimod has been investigated in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials investigating resiquimod, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open).

HLA-A*01 Positive, HLA-A*02 Positive, and HLA-A*03 Positive are the most frequent biomarker inclusion criteria for resiquimod clinical trials.

Melanoma and primary cutaneous T-cell non-hodgkin lymphoma are the most common diseases being investigated in resiquimod clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Resiquimod
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Resiquimod
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating resiquimod and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
r848 compound, s-28463, r848, s 28463, 4-amino-2-ethoxymethyl-alpha,alpha-dimethyl-1h-imidazo(4,5-c)quinoline-1-ethanol, 4-amino-2-(ethoxymethyl)-alpha,alpha-dimethyl-1h-imidazo[4,5-c]quinoline-1-ethanol, r-848, r 848, 144875-48-9, resiquimod, resiquimod, cd 11301, cd11301, resiquimod gel cd11301
Drug Categories [2]:
TLR8 agonists
Drug Target(s) [2]:
TLR7, TLR8
NCIT ID [1]:
C148143

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.